The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis c virus activity without detectable cross-resistance

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3327-3334

  Chatterji, Udayan ^a   Garcia Rivera, Jose A ^a   Baugh, James ^a   Gawlik, Katarzyna ^a   Wong, Kelly A ^b   Zhong, Weidong ^b   Brass, Clifford A ^c   Naoumov, Nikolai V ^c   Gallay, Philippe A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; BOCEPREVIR; CYCLOPHILIN A; DACLATASVIR; MERICITABINE; NONSTRUCTURAL PROTEIN 5A; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; CYCLOPHILIN; CYCLOSPORIN; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENTIATION; GENOTYPE; HEPATITIS C VIRUS; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REPLICON; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMAN; METABOLISM; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYCLOPHILIN A; CYCLOPHILINS; CYCLOSPORINE; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; REPLICON; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84901278663     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00016-14     Document Type: Article

References (24)

1. Dienstag JL, McHutchison JG. 2006. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130:231-264. http://dx.doi.org/10.1053/j.gastro.2005.11.010.
2. Alter MJ. 2007. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13:2436-2441.
3. Soriano V, Madejon A, Vispo E, Labarga P, Garcia-Samaniego J, Martin- Carbonero L, Sheldon J, Bottecchia M, Tuma P, Barreiro P. 2008. Emerging drugs for hepatitis C. Expert Opin. Emerg. Drugs 13:1-19. http://dx.doi.org/10.1517/ 14728214.13.1.1.
4. Bartenschlager R, Lohmann V, Penin F. 2013. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat. Rev. Microbiol. 11:482-496. http://dx.doi.org/10.1038/nrmicro3046.
5. Lin K, Gallay P. 2013. Curing a viral infection by targeting the host: the example of cyclophilin inhibitors. Antiviral Res. 99:68-77. http://dx.doi.org/10.1016/j.antiviral.2013.03.020.
6. Gallay PA, Lin K. 2013. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des. Dev. Ther. 7:105-115. http://dx.doi.org/10. 2147/DDDT.S30946.
7. Robinson M, Yang H, Sun SC, Peng B, Tian Y, Pagratis N, Greenstein AE, Delaney WE, IV. 2010. Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a. Antimicrob. Agents Chemother. 54:3099-3106. http://dx.doi.org/10.1128/AAC.00289-10.
8. Vrolijk JM, Kaul A, Hansen BE, Lohmann V, Haagmans BL, Schalm SW, Bartenschlager R. 2003. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J. Virol. Methods 110:201-209. http://dx.doi.org/10.1016/S0166-0934(03)00134-4.
9. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796. http://dx.doi.org/10.1038/nm1268.
10. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R. 2006. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 80:5308-5320. http://dx.doi.org/10.1128/JVI.02460-05.
11. Saeed M, Scheel TK, Gottwein JM, Marukian S, Dustin LB, Bukh J, Rice CM. 2012. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob. Agents Chemother. 56: 5365-5373. http://dx.doi.org/10.1128/AAC.01256-12.
12. Prichard MN, Shipman C, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-205. http://dx.doi.org/10.1016/ 0166-3542(90)90001-N.
13. Garcia-Rivera JA, Bobardt M, Chatterji U, Hopkins S, Gregory MA, Wilkinson B, Lin K, Gallay PA. 2012. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir. Antimicrob. Agents Chemother. 56:5113-5121. http://dx.doi.org/10. 1128/AAC.00919-12.
14. Grisé H, Frausto S, Logan T, Logan T, Tang H. 2012. A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates alisporivir susceptibility. J. Virol. 86:4811-4822. http://dx.doi.org/10.1128/JVI.06641-11.
15. Wyles DL. 2012. Beyond telaprevir and boceprevir: resistance and new agents for hepatitisCvirus infection. Top. Antivir. Med. 20:139-145. http://www.iasusa.org/sites/default/files/tam/20-4-139.pdf.
16. Griffel L, Bao W, Orsenigo R, Guo V, Wu M, Loeffler J, Brass C, Avila C, Naoumov NV. 2013. Interferon (IFN)-free alisporivir has a better overall safety profile compared to IFN-containing treatment: a pooled analysis of the ALV development program. J. Hepatol. 58(Suppl 1):S336-S337. http://download. journals.elsevierhealth.com/pdfs/journals/0168-8 278/PIIS0168827813608235.pdf.
17. Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G, Vandamme AM, Bartenschlager R, Gallay P, Lippens G, Neyts J. 2010. DEB025 (alisporivir) inhibits hepatitisCvirus replication by preventing a cyclophilinAinduced cis-trans isomerisation in domain II of NS5A. PLoS One 5:e13687. http://dx.doi.org/10.1371/journal.pone. 0013687.
18. Pawlotsky JM, Chen D, Tang Y, Bao W, Ke J, Yu J, Lin K, Wiedmann B, Wong KA, Jones CT, Avila C, Naoumov NV, Li B. 2013. Multiple mutations in domain II of NS5A identified in genotype 2/3 VITAL-1 study breakthrough patients are required to reduce susceptibility to alisporivir in vitro. J. Hepatol. 58(Suppl 1):S493. http://download.journals.elsevierhealth.com/pdfs/journals/0168-8278/ PIIS0168827813612155.pdf.
19. Wang C, Sun JH, O'Boyle DR, II, Nower P, Valera L, Roberts S, Fridell RA, Gao M. 2013. Persistence of resistant variants in hepatitis C virusinfected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob. Agents Chemother. 57:2054-2065. http://dx.doi.org/10.1128/AAC.02494- 12.
20. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, Vogt A, Catanese MT, Satoh T, Kawai T, Akira S, Law M, Rice CM, Ploss A. 2013. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 501:237-241. http://dx.doi.org/10.1038/nature12427.
21. O'Boyle DR, II, Sun JH, Nower PT, Lemm JA, Fridell RA, Wang C, Romine JL, Belema M, Nguyen VN, Laurent DR, Serrano-Wu M, Snyder LB, Meanwell NA, Langley DR, Gao M. 2013. Characterizations of HCV NS5A replication complex inhibitors. Virology 444:343-354. http://dx.doi.org/10.1016/j.virol.2013.06.032.
22. Foster TL, Gallay P, Stonehouse NJ, Harris M. 2011. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J. Virol. 85:7460-7464. http://dx.doi.org/10. 1128/JVI.00393-11.
23. Foster TL, Belyaeva T, Stonehouse NJ, Pearson AR, Harris M. 2010. All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding. J. Virol. 84:9267-9277. http://dx.doi.org/10.1128/JVI.00616-10.
24. Tellinghuisen TL, Marcotrigiano J, Rice CM. 2005. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435:374-379. http://dx.doi.org/10.1038/nature 03580.